For research use only. Not for therapeutic Use.
PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research[1].
| Catalog Number | I040530 |
| CAS Number | 2988890-20-4 |
| Synonyms | 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-[(3S,5S)-3,5-dimethylpiperazin-1-yl]-N-(1-methylcyclopropyl)indazole-6-sulfonamide |
| Molecular Formula | C20H25F2N7O2S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H25F2N7O2S2/c1-11-9-28(10-12(2)24-11)15-6-13(33(30,31)27-20(3)4-5-20)7-16-14(15)8-23-29(16)19-26-25-18(32-19)17(21)22/h6-8,11-12,17,24,27H,4-5,9-10H2,1-3H3/t11-,12-/m0/s1 |
| InChIKey | AQOUTSJIZZVANZ-RYUDHWBXSA-N |
| SMILES | CC1CN(CC(N1)C)C2=CC(=CC3=C2C=NN3C4=NN=C(S4)C(F)F)S(=O)(=O)NC5(CC5)C |
| Reference | [1]. Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1. |
